Health Catalyst’s second quarter was marked by a notable decline in sales, which management attributed primarily to the ongoing impact of client migrations and a reduction in lower-margin services. The company’s decision to divest Vitalware, its revenue cycle management business, was described by CEO Ben Albert as necessary to focus on areas of highest conviction, despite the near-term revenue impact. Albert acknowledged the structural challenges facing health systems and emphasized that the divestiture provided immediate benefits, including significant debt elimination and a cleaner balance sheet. Management’s tone was cautious, highlighting the early stages of a multiyear transformation and the need to navigate persistent revenue headwinds.
Is now the time to buy HCAT? Find out in our full research report (it’s free for active Edge members).
Health Catalyst (HCAT) Q2 CY2026 Highlights:
- Revenue: $70.49 million vs analyst estimates of $69.05 million (12.7% year-on-year decline, 2.1% beat)
- Adjusted EPS: $0.04 vs analyst estimates of $0.03 (in line)
- Adjusted EBITDA: $9.92 million vs analyst estimates of $9.43 million (14.1% margin, 5.2% beat)
- The company dropped its revenue guidance for the full year to $247.5 million at the midpoint from $262.5 million, a 5.7% decrease
- EBITDA guidance for the full year is $18.25 million at the midpoint, below analyst estimates of $32.09 million
- Operating Margin: -51.8%, down from -46% in the same quarter last year
- Billings: $54.75 million at quarter end, down 28.1% year on year
- Market Capitalization: $134.7 million
While we enjoy listening to the management’s commentary, our favorite part of earnings calls is the analyst questions. Those are unscripted and can often highlight topics that management teams would rather avoid or topics where the answer is complicated. Here is what has caught our attention.
Our Top 5 Analyst Questions From Health Catalyst’s Q2 Earnings Call
- Luis (Citi): asked whether the decline in guidance, excluding the Vitalware divestiture, would have been reiterated. CFO Jason Alger clarified that the main driver was the removal of Vitalware, but also noted increased investment in team members and core products.
- Luis (Citi): questioned whether additional divestitures are under consideration following the Vitalware sale. Alger responded that the current focus is on executing the transformation and validating the company’s highest-conviction opportunities, not on further portfolio changes.
Catalysts in Upcoming Quarters
Looking ahead, our analysts will be watching (1) progress on Project Nexus and the resulting cost savings, (2) the pace and impact of client migrations to the Ignite platform and related churn trends, and (3) the company’s ability to deliver new analytics and AI-driven products that resonate with health system clients. Additionally, we will monitor whether the company can maintain a strong balance sheet and adapt its services business to shifting customer needs.
Health Catalyst currently trades at $1.76, down from $2.31 just before the earnings. Is the company at an inflection point that warrants a buy or sell? The answer lies in our full research report (it’s free).
The Best Stocks for High-Quality Investors
ALSO WORTH WATCHING: Top 5 Momentum Stocks. The best time to own a great stock is when the market is finally noticing it. These aren’t just high-quality businesses. Something is happening with them right now. Elite fundamentals meet near-term momentum — both boxes checked at the same time.
Find out which stocks our AI platform is flagging this week. See this week’s Strong Momentum stocks — FREE. Get Our Strong Momentum Stocks for Free HERE.
Stocks that have made our list include now familiar names such as Nvidia (+1,460% between June 2020 and June 2025) as well as under-the-radar businesses like the once-small-cap company Comfort Systems (+1,154% between June 2020 and June 2025). Find your next big winner with StockStory today.
